Skip to Main Content

Paper Details

Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial).
BMJ Open
0
2023
Author NameAffiliation
Jay L KoynerUniversity of Chicago Pritzker School of Medicine
Daniel EngelmanBaystate Medical Center
Claudio RoncoInternational Renal Research Institute of Vicenza, San Bortolo Hospital of Vicenza
Alexander ZarbockUniversity Hospital Munster
  • 1 - 4

Datasets

Release 1.2